

INDICATION:

Androgen deprivation therapy (ADT): Clinically localized disease, Regional disease, Castration-naïve M0 or M1, or Castration-resistant M0 or M1

REFERENCES:

1. [NCCN Guidelines® for Prostate Cancer V.1.2022.](#)
2. [McLeod DG, et al. *BJU Int.* 2006;97\(2\):247-54.^a](#)
3. [Shipley WU, et al. *N Engl J Med.* 2017;376\(5\):417-428.^a](#)
4. [Schellhammer PF, et al. *Urology.* 1997;50\(3\):330-6.^b](#)
5. [Basch E, et al. *J Clin Oncol.* 2014;32\(30\):3436-48.^b](#)

NCCN SUPPORTIVE CARE:

1. *Emetic risk:*
Days of Bicalutamide Oral Low/Minimal
2. *Febrile Neutropenia Risk:* Refer to Myeloid Growth Factor algorithms in the [NCCN Guidelines for Hematopoietic Growth Factors](#)

CHEMOTHERAPY REGIMEN

To ensure safe and effective treatment with oral anticancer therapy, develop a treatment plan with the patient that includes medication access, goals of therapy, frequency of monitoring (eg, visits, labs, symptom checks), instruction for toxicity management, screening of concomitant medications, and adherence assessment.

28-day cycle for 2 years (clinically localized disease)

- **Bicalutamide** 150 mg PO daily on Days 1 – 28
 - Bicalutamide is available as 50 mg tablets.

OR

28-day cycle – refer to NCCN Guidelines for Prostate Cancer for duration of therapy based on clinical setting

- **Bicalutamide** 50 mg PO daily on Days 1 – 28
 - Bicalutamide is available as 50 mg tablets.

Depending on the clinical setting, bicalutamide 50 mg is given in combination with an LHRH agonist with or without Docetaxel. Please see order templates PRO10: Docetaxel or PRO13: Goserelin, PRO14: Histrelin, PRO15: Leuprolide Acetate, PRO16: Triptorelin, and PRO29: Leuprolide Mesylate for LHRH agonist options.

SUPPORTIVE CARE**Antiemetic Therapy**

PRN for breakthrough: All patients should be provided with at least one medication for breakthrough emesis. Please consult the [NCCN Guidelines for Antiemesis](#) for appropriate antiemetic therapy.

Other Supportive Therapy

- For bicalutamide: This agent may cause a decrease in bone mineral density. Consider vitamin D and calcium supplementation when appropriate.

MONITORING AND HOLD PARAMETERS

- CBC with differential should be monitored as clinically indicated for potential dose modification.
- For bicalutamide:
 - This agent may prolong the QT interval and may lead to torsade de pointes. Consider EKG monitoring prior to initiation of therapy and as clinically indicated. Check patient medication profile for concomitant administration of QT-prolonging drugs, including antiemetics. Review drug package insert for additional information.
 - This agent may cause interstitial lung disease/pneumonitis. Monitor for nonspecific respiratory signs and symptoms, including hypoxia, cough, or dyspnea. Modification or discontinuation of therapy may be warranted. Refer to drug package insert for specific recommendations.
 - Monitor bone mineral density prior to initiation of therapy and as clinically indicated.
 - Liver function should be monitored prior to initiation of therapy and as clinically indicated for potential dose modification or discontinuation.
 - Serum glucose should be monitored as clinically indicated.
 - Calcium and vitamin D should be monitored as clinically indicated. Supplemental medication should be administered as needed.
 - Monitor serum testosterone and PSA levels regularly to ensure efficacy of androgen deprivation therapy over time.

Template continued on page 2

NCCN Chemotherapy Order Templates (NCCN Templates®) are peer-reviewed statements of the consensus of its authors derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) regarding their views of currently accepted approaches to treatment. An NCCN Template does not constitute an order. Any clinician seeking to treat a patient using the NCCN Templates® is expected to use independent medical judgment in the context of individual clinical circumstances of a specific patient's care or treatment. NCCN disclaims all warranties, express or implied including, without limitation, the implied warranties of merchantability and fitness for a particular purpose. NCCN does not warrant the accuracy, currency, or completeness of the NCCN Templates or make any representation regarding the use or the results of the use of the NCCN Templates in treatment. In no event shall NCCN or its members be liable for any damages including, without limitation, incidental, indirect, special, punitive, or consequential damages arising out of or in connection with the use of the NCCN Templates including, without limitation, loss of life, loss of data, loss of income or profit, losses sustained as a result of any injury to any person, or loss or damage to property or claims of third parties.



SAFETY PARAMETERS AND SPECIAL INSTRUCTIONS

- For bicalutamide:
 - Take with or without food.
 - This agent has multiple potential drug-drug and/or drug-food interactions. Review patient medical profile and drug package insert for specific drug and food interactions and recommendations.

NCCN Chemotherapy Order Templates (NCCN Templates®) are peer-reviewed statements of the consensus of its authors derived from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) regarding their views of currently accepted approaches to treatment. An NCCN Template does not constitute an order. Any clinician seeking to treat a patient using the NCCN Templates® is expected to use independent medical judgment in the context of individual clinical circumstances of a specific patient's care or treatment. NCCN disclaims all warranties, express or implied including, without limitation, the implied warranties of merchantability and fitness for a particular purpose. NCCN does not warrant the accuracy, currency, or completeness of the NCCN Templates or make any representation regarding the use or the results of the use of the NCCN Templates in treatment. In no event shall NCCN or its members be liable for any damages including, without limitation, incidental, indirect, special, punitive, or consequential damages arising out of or in connection with the use of the NCCN Templates including, without limitation, loss of life, loss of data, loss of income or profit, losses sustained as a result of any injury to any person, or loss or damage to property or claims of third parties.